Improvement of Knowledge About the Arthrogenic Muscle Inhibition in the Aftermath of Knee Trauma.

NCT ID: NCT03950024

Last Updated: 2024-08-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-10-29
• Study Completion Date: 2024-06-11

Brief Summary

Arthrogenic Muscle Inhibition (AMI) is one of the classic complications occurring in the aftermath of knee trauma; AMI is grossly defined as a lack of extension due to quadriceps inhibition and hamstring contracture. However, its origins remains unknown with a strong suspicion for a central brain origin. It could be the missing link explaining this lack of extension following an anterior cruciate ligament (ACL) rupture. The primary hypothesis of this study is that a difference in activation of motor brain areas exists in patients with an ACL rupture, between those with AMI or without. The second hypothesis is that this difference could be seen on brain functional MRI.

Detailed Description

AMI leads to quadriceps atrophy, persistent knee pain, dynamic instability, and a higher rate of osteoarthritis. A recent literature review suggests that the AMI phenomenon is multifactorial, but not widely known and poorly understood. Known mechanisms include impaired motor function at rest, impaired transmission of information from joint sensory receptors, impaired excitability of the spinal reflex and impaired cortical activity. Several studies have suggested a link between ACL rupture and central nervous system reorganization. Among the neurophysiological investigations explored are the evoked somesthesic potentials, electroencephalography, and transcranial magnetic stimulation (TMS). However, these mechanisms alone do not explain the phenomenon in its entirety, suggesting that there are other mechanisms. Furthermore, no study has used functional brain MRI to assess the existence of similar changes in AMI.

This study plans to compare two groups of patients with an ACL rupture: a group with AMI, and a group without AMI. Both groups will undergo a functional brain MRI in order to analyse any modification of the sensory-motor network connectivity that could occur.

Conditions

Anterior Cruciate Ligament Rupture

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

with arthrogenic Muscle Inhibition

Group Type: EXPERIMENTAL

functional brain MRI

Intervention Type: DIAGNOSTIC_TEST

The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)

without arthrogenic Muscle Inhibition

Group Type: ACTIVE_COMPARATOR

functional brain MRI

Intervention Type: DIAGNOSTIC_TEST

The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)

Interventions

functional brain MRI

The functional brain MRI realized will be a examination with a resting sequence and a sequence during a movement imagination task. (knee bent)

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• male patient, right-handed,
• with a severe right knee sprain in the event of ACL rupture,
• occurrence of trauma within 4 weeks prior to inclusion,
• with a score of ≥ 8/10 on the Edinburgh Manual Laterality Questionnaire, -affiliated or benefiting from public health services.

Exclusion Criteria

• person presenting any of these conditions : professional player / athlete, -contraindication to the MRI examination (claustrophobic patient, patient with a metallic element),
• patient already operated on with ligament damage to the knee other than ACL,
• patient with iterative ACL rupture,
• patient who has undergone contralateral ligament reconstruction,
• patient with multi-ligamentary knee injury,
• patient refusing to be informed of any abnormality detected on brain MRI, -protected patient (adults under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision).

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 30 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Toulouse

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Etienne CAVAIGNAC, MD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Toulouse

Locations

Pierre Paul Riquet Hospital

Toulouse, Occitanie, France

Countries

France

Other Identifiers

2019-A00479-48

Identifier Type: OTHER

Identifier Source: secondary_id

RC31/19/0029

Identifier Type: -

Identifier Source: org_study_id